These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38285444)

  • 1. Emergency Department Access to Buprenorphine for Opioid Use Disorder.
    Herring AA; Rosen AD; Samuels EA; Lin C; Speener M; Kaleekal J; Shoptaw SJ; Moulin AK; Campbell A; Anderson E; Kalmin MM
    JAMA Netw Open; 2024 Jan; 7(1):e2353771. PubMed ID: 38285444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder.
    D'Onofrio G; Edelman EJ; Hawk KF; Chawarski MC; Pantalon MV; Owens PH; Martel SH; Rothman R; Saheed M; Schwartz RP; Cowan E; Richardson L; Salsitz E; Lyons MS; Freiermuth C; Wilder C; Whiteside L; Tsui JI; Klein JW; Coupet E; O'Connor PG; Matthews AG; Murphy SM; Huntley K; Fiellin DA
    JAMA Netw Open; 2023 Apr; 6(4):e235439. PubMed ID: 37017967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description.
    Regan S; Howard S; Powell E; Martin A; Dutta S; Hayes BD; White BA; Williamson D; Kehoe L; Raja AS; Wakeman SE
    J Addict Med; 2022 Mar-Apr 01; 16(2):216-222. PubMed ID: 34145185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.
    Ross RK; Inose S; Shulman M; Nunes EV; Zalla LC; Burlew AK; Rudolph KE
    JAMA Netw Open; 2024 Oct; 7(10):e2436612. PubMed ID: 39365581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).
    D'Onofrio G; Edelman EJ; Hawk KF; Pantalon MV; Chawarski MC; Owens PH; Martel SH; VanVeldhuisen P; Oden N; Murphy SM; Huntley K; O'Connor PG; Fiellin DA
    Implement Sci; 2019 May; 14(1):48. PubMed ID: 31064390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.
    Hawk KF; D'Onofrio G; Chawarski MC; O'Connor PG; Cowan E; Lyons MS; Richardson L; Rothman RE; Whiteside LK; Owens PH; Martel SH; Coupet E; Pantalon M; Curry L; Fiellin DA; Edelman EJ
    JAMA Netw Open; 2020 May; 3(5):e204561. PubMed ID: 32391893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial and ethnic disparities in emergency department-initiated buprenorphine across five health care systems.
    Holland WC; Li F; Nath B; Jeffery MM; Stevens M; Melnick ER; Dziura JD; Khidir H; Skains RM; D'Onofrio G; Soares WE
    Acad Emerg Med; 2023 Jul; 30(7):709-720. PubMed ID: 36660800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.
    Herring AA; Vosooghi AA; Luftig J; Anderson ES; Zhao X; Dziura J; Hawk KF; McCormack RP; Saxon A; D'Onofrio G
    JAMA Netw Open; 2021 Jul; 4(7):e2117128. PubMed ID: 34264326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization.
    Axeen S; Pacula RL; Merlin JS; Gordon AJ; Stein BD
    JAMA Netw Open; 2024 Sep; 7(9):e2435478. PubMed ID: 39320889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments.
    Kumar P; Kaliamurthy S; Thomas J
    Pediatrics; 2024 Aug; 154(2):. PubMed ID: 38966873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the association between specific post-overdose care services in emergency departments and subsequent treatment engagement.
    Chambers LC; Hallowell BD; Samuels EA; Daly M; Baird J; Beaudoin FL
    J Am Coll Emerg Physicians Open; 2023 Feb; 4(1):e12877. PubMed ID: 36643599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.